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A mesonably sensitive and sue& n~uinvusive t st for doxorubi- 
tin eardiotaxicity is needed: In ndditian, few data exist on the 
short. and lon~term effeetsof duxorubiein on diastolic tilling. To 
determine ii uubed Duuuler indexes of diastcdie Rlline muld 
predict doxorubicin-induced systulic dysfuoetiun, M Qatients 
Once” age lls e 12 years) were Qrespectivety studied before 
receiving ebemotberepy (cantrat) and 3 weeks after obteinlna 
etmudative doses of doxurubiein. 
In nine patients developing doxoruhicio-induced systolic dya. 
funetien @hat is, a decrease in ejection fraction by at6 ejection 
rr~rttou ““its I caac. I the iro”ohlme,rlc relaxation timewas 
Iian preceded a significant decrease in ejeeiiun fraction. Other 
Ijuppler indexes of tilling were tutpaired after duxorubicin therapy 
but occurred simultaneously with the deereare inejection fraction. 
Doxorubicin has proved to be an effective antineoplastic 
agent in the treatment of malignant lymphoma, leukemiaand 
several solid tumors (l-3). Uufortunately, serious and Qo- 
tentially irreversible dose-related cardiotoxicitv may occur 
with iti administration (4,5). Congestive heon failure devol- 
ops in >30?? of patients receiving >550 m&n’ of doxorubi- 
tin and may occur with lesser doses (4-7). Thus, achieving 
a cumulative dose of doxorubicin that is maximally ehica- 
cious with an acceptable degree of csrdiotoxicity remains 
one of the most difhcult dilemmas faced by the oncologist 
and cardiologist. 
Several noninvasive techniques such as electrocardio- 
graphy, phonocardiography and M-mode echocardiography 
are insensitive and nonspecific in monitoring dnxnrubicin- 
induced cardiotoxicity (S-10). Endomyacardial biopsy has 
been useful in guiding doxorubicin therapy. but it is an 
A >37% tnereere in isuvotunretric retuxatfun thne was 78% 
(7 of 9) sensitive end a890 (15 of 17) sQe&e far predicting the 
ultimate development of duxerublcln-lndueed syrtohc dysfune- 
tiun. In I5 patients tudied 1 h after the firs1 treatment, duxuru- 
bicio suhanced Doppler indexes cd filliig and shurtened isuwlu- 
metric relax&m time. In La patients, indexes or tilting renudnrd 
impsired and isawdunetrtc retnxutien tine wss prulenaed 
3 months ufter the 1st duxurubiebt dose. 
In conclusfon, duxnrubicinbtduced systdie dysfunction is re. 
liably Qredtcted by prulongetion of DuQQ~ePderived tsowbunetrie 
relsxatiuu time. Early eftrradministretiun, doxurubtctn euhuneer 
tittina end isavab,u,etrte r ,exetfuu tbue. The adverse ffects or 
dexorubicin on both veriiables per&t et trust 3 mantbs efter 
cesselion of treattueutl 
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invasive procedure with associated risks and complications 
(&IO-12). Left ventricularejectionfractiou at rest is used by 
many oncologists to guide doxoruhicin therapy (13-15). 
However, mild heart failure may not be well predicted by 
ejection fraction at rest (13). Although a decrease in ejection 
fraction with exercise may improve the Sensitivity of radio- 
nuclide angiography, stress testing has not gained Qopularhy 
because many patients with a malignant neoplasm are debil- 
itated and incapable of exercising. Thus, it is not certain 
which noninvasive studies are most useful in the early 
detection of doxorubicin cardiotoxicity or in guiding the 
maximally tolerable dose of doxorubicin for a eiven natient. 
Nume;ous studies have xamined the effec;of d&oruhi- 
tin on systolic function and it has been shown (16) that 
doxorubicin can cause endomywardial fibrosis and result in 
impaired diastolic function as manifested by restrictive phys- 
iology. Some recent work (17.18) has suggested tbst di.+stolic 
filling abnormalities may precede systolic dysfunction in 
patients receiving doxowbicm. However, it is unknown 
whether impaired systolic function due to doxorubicin can 
be reliably predicted by any noninvasive index of diastolic 
filling. In addition, few data exist an the short- and poten- 
tially long-term effect of doxorubicin on diastolic filling (19). 
Thus, the goals of the present study were to determine the 
short- and long-term effect ofdoxoruhicin on diartc!i; Xling 
and the ability of pulsed Doppler indexes of diastobc func- 
tion to predict doxorubicin-induced sysroi~c dysfunctmn. 
Methods 
Study patients. Thirty-b,ir patients scheduled to begin 
chemotherapy with doxorubicin in an antnpated cumulative 
dose of 2200 m&n’ for any mabgnant neoplam were 
enrolled in the study. Inclusion criteria included age 218 
years. normal sinus rhythm and no prior ireament wth any 
anrhracycline derivative (for wxm:lc. doxorubicin and 
daunomydn). Exclusion criteria :ncluded chest u-radiation 
therapy between the first dose and up IO 3 weeks after the 
last dose of doxorubicir,, left .wtricular ejection fraction 
~55% before therapy, more than imild aoriic or mitidl 
regurgitation as assessed $y pulsed and Doppler color flow 
echocardiography (20-B). aortic or mini valve stcnow, 
(24,25). a prior history ofcardiac disease or congestive hear! 
failure. suspected coronary anery disease (that is, a history 
of angina or myocardial infarction, abnormal fin&no= nn ? 
lblead electrocardiogram (ECG) or segmental or global 
wall motion abnormality on two-dimenstonal echacardiog- 
raphy), failure to achieve a cumulative doxorublcin dose of 
s2M) mg/m’ for reasons unrelated to cardiotoxicity and a 
technical:y inadequate rwodimension$ or Doppler echocar- 
diagram. Eight patients were excluded for the following 
reasons: a technically inadequate echocardiogram (n = 3). a 
cumulative doxarubicin dose GUI mgln’ In = 4) and an 
ejection fraction <SS% before therapy In = I). Thus, the 
study group consisted of 26 patients (22 women and 4 men) 
with a mean age of 48 + I2 years (range 20 to 69) being 
treated for breast carcinoma (n = 19). lung czcinoma (n = 
31, rectal carcinoma (n = I). Hodgkin’s lymphoma 01 = I) 
and sarcoma of the tongue (II = I) or pelvis co = I). Five 
patients had systemic hypertension. 
The defrnifion of doxorrrbicill-indltced ryrtolic dy.$m- 
rim wad determined prospectively and based an the follow- 
ing three criteria: I) ejection fraction ~55% after doxorubl- 
tin, 2) decrease in ejection fracrion of 210 ejection fraction 
units from the control value after doxorubicin. and 31 con- 
tinued ejection fraction measurements of ~55% after criteria 
I and 2 were met. Written informed convent was obtained 
from all patients. The study protocol was deemed ethical and 
approved by the Human Studies Committee at our institution. 
Study protocol. Doxorubicin was administered imrave- 
nously as B bolus injection every 3 weeks in doses of 40 (n = 
2). 50 (n = 8) and 60 (n = 16) mpimz, Patients also received 
noncardiotoxic doses of cyclophosphamide, vincristine. 
5.Ruarouracil. bleomycin or methylprednirolone. Each pa- 
tient war evaluated within 24 h before the lint txatment, 
3 weeks after each treatment in which the cumulative 
doxorubicin dose was 40 to 60, KM to IZO, 15(11o 18Oand 200 
to 240 mgIm22, and 3 weeks after the peak doxombiein dose. 
Fifteen patients selected atrandom were studied I h after the 
first doxorubicin treatment (early group). Twenty-two pa- 
iicots lucre sludied 3 months after the last doxorubicin 
treamtcnt lime erouo). 
Prrrienl n&on& included a history and physical exam- 
matloo 10 assess for hean failure using the New York Heart 
Associatmn xireria. comprehensive two-dimcnsi. oat, 
pulsed and Doppler color Row echocardiogaphy and ihe 
average of !hree systemic bl& pressure determination: 
Kritikon. Dinamap model IM SXIPI. Echocardiographic 
studies were performed with ibe patient m the left xmire- 
cumbenr posmon and analyzed without knowledge of clini- 
cal vanables such as age. gender. height, weight and doxo- 
rubicin dose. Two-dimensional and pulsed Doppler 
echocardiograms wcrc each analyzed without knowledge of 
the results of the other echocardiographic study. Studies 
selected for determination of intraobserver, isterotservzr 
sod 3.we& bioio$c variability of measured variables were 
examined 23 months apart. 
Echoeardioenohy and anaMs. With use of a ohased- 
array echocardi&phic maeh& (Hewlet:-Packard: model 
77020) with a 2.5.MHz tranrducer, twodimensional images 
were recorded on videotape in the left w!ticelar paraster- 
nal long-axis view. short-axis view at the mitral valv; and 
papillary muscle levels and apical four-chamber, five- 
chamber. two-chamber and long-axis views. In an attempt to 
minimize foreshortening in the left ventricular long&.~s 
view. an apd window was obtained that allowed rotation 
from the apwal four-chamber to the twwhamber end long- 
axis views without apparent shifting of the apex from the 
center of the echocardiographic sector. Pulsed Doppler 
studv of mitral inflow was txtionned by alimtittr! the sample 
volume cursor on the &mediate ve&i&larside of ihc 
mitral anulus from an apical four-chamber view as previ- 
ously described (26.27). Proper placement of th< sample 
volume was confirmed by assessing the position of the 
cursor with the simultaneous real time two-dimensional 
image. The sample volume cursor was placed in an interme- 
dime position between the outflow tract and mitral valve to 
obtain left ventricular outtlow and inflow velocities. All 
Doppler srudies were recorded on hard copy 81 100 mmls. 
Color Row (velocity variance mode) and pulsed Doppler 
imaging were performed from appropriate views to exclude 
valvular regurgitation. To minimize variability in recorded 
studies. all echoeardiogram. in a given patient were per- 
formed by the same sonogmpher. 
With &e of a microcomputer interfaced with a Summa- 
graphics plus digitizing tablet and customized software, the 
mitral Doppler velocity curve of five consecutive cardiac 
cycles wns digitized as previously described (X.27). Individ- 
uaI indexes were obtained from each cardiac cycle and 
averaged. Diastolic filling indexes included peak early tilling 
velocity. peak early to peak atrial tilling velocity ratio, mean 
deceleration rate of early filling. decelemlion time (measured 
as rime mtcrval from peak early filling velociiy to the time 
where an imaginary line entrapalaled from the dcsccnding 
limb of the early filling cwve reachr> zero) and accelemlion 
time (measured as time from onset of mitral inflow to peak 
Figure 1. Pulsed Doppler echocardiographic lracing obtained in an 
iotemediaLe posiiioo between the left venrricular outflow tracf and 
7‘ixal vakc. The isnvalumerric rela*ation ume WR.Tl Was mea- 
sured from the end oi outflow to the beginning of inflow ECC = 
elecllocardiogram. 
early filling velocityJ. Iso~iohictric relaxation time was 
mcxxd from the end of left ventricular oulflow to Ihe 
beginning of inflow (Fig. I). 
With use of B video compuiersys?em, the lelt veniricular 
endocardial surface was digitized on end-diastolic (that is. 
maximal area) and end-systolic (that is. roinimal area) frames 
to obtain cross-sectional areas at the shon-axis mitrai valve 
(AM) and papdlary muscle (API level. The leading edge 
wrhnique as recommended by Wyatt et. al. (28) was used :c 
trace endocardial edges. Ventricular length 0-1 at end- 
diistole and end-systole was measured by wing an apical 
four-chamber view from Ihe apex to the midpoint of an 
imainarv line at the mitral anulos. Ventricular volume (VI in 
end~dias~ole and end-systole was calculated by lhe n&&d 
Simpson’s method, where V = (L x AM/31 + ([AM + API 
x W6) + CL x AP/9) (29-33). Three ejection fraction dc- 
lermioations calculated in Ihe usual Fashion were avelagcd. 
Statistical nalysis. Values are cxpressed as mean value 
? I SD. Analysis of vanonce for repeated measures IScheffe 
F test) was wed 10 assess differences in serial echocardio- 
graphic and blood pressure variables. An unpaired I test was 
used to assess differences between two groupc. Chi-square 
analysts with correction for the size of the stody groups was 
performed when appropriate. Correlations between Doppler 
variables and ejection fraction were sought with univariate 
Icast squares and multiple siepwire linear regression scaly 
ses (Statview-Sltt, Brainpower, 1nc.I. The percent vari- 
ability (that is. intraobserver. interobserver and 3.week 
biologic variability) m a given variable was calculated as the 
absolute difference in the variable measured at Iwo points in 
lime divided by the mean vah~e of the two measurements 
times 100%. A p value < 0.05 was considered slalistically 
sagnificant. 
Results 
Erect of doxorubicin on systolic function. Nine of the 26 
patients developed doxorobicin-induced systolic dysfonc- 
lion. In this group. ejection fraction began to decrease after 
a cumulative doxorubicin dose of I50 to 180 m&n’ from 
66 2 7% to 58 ? 7% (p < 0.02). with the maximal decrease 
occurring after the penk doxorubicin dose (45 * 10%. p < 
0.001) (Table I). The ~Jecwase in ejection iraclion was due 10 
an increase in end-systolic vulume. End-diastolic volume 
was unchanged. The isovolumetric relaxation time became 
prolonged a~ compared with control values after a cumula- 
tive doxorubicin dose of I00 to 120 ms/mz (66 i I8 to 84 + 
24 ms, p < 0.05). The maximal prolongation in isovolumetric 
relaxaion tmx occurred tier the peak doxarubicin dose 
(I IS + 24 ms. p i O.001) A significant prologation in 
deceleration lone and decrease in mean dcccleration rate of 
early filling and peak early 10 peak atria, filling velocity miio 
occurred after a doxorubicin dose of I50 10 180 mdm’ (Fig. 
2). In the 17 subjects not meeting criteria for doxorubicin- 
induced systolic dy&mc,ion. ejection fraction, end-diastolic 
volume, end-systolic volume and all Doppler variables were 
unchanged with the exception of isovolumetric relaxation 
time, which slightly prolonged after a cumulalive doxorubi- 
tin dose of I50 to I60 mglmzlTable 2). Hear, rate. dastolic 
filling time and blood pressure were unchanged aRcr doro- 
rubicin in bolh groups. 
Prolonged isovolumetric relaxation time. In the nine pa- 
tients who ultimately developed doxorubicin-induced sys- 
tolic dysfunction, isovolumetric relaxation time was consis- 
tently prolonged before ejection fraction significanlly 
decreased (Fig. 3 and 4). An increase in isov&me!ric 
relaxation time >37% immediately before the cumuId,ws 
doxorubicin dose that resulted in systolic dysfunction pre- 
dicted development of doxorubicin cardiotoxicity in ?&c/o 
(seven of nine patients) (Fig. 5). One of the nine patients 
(P&n, I) dereloped class IV congestive hear, failure 3 
weeks after the last daxorubicin dose and died of cardiogenic 
shock after a cumularive doxorubicin dosage of 200 mglm’. 
In the patien,. ejeclion fraction was normal before the Iart 
doxorublcin dose, but irovaluoeuic relaxation lime had 
mcreased by 57% (Fig. I and 21. In the I7 subjects who did 
not develop systolic dysfunction, 88% (IS of 171 had no 
prolongation in isovolumetric relaxation time >37% 
throughout the course of ,reatme”, (Rg. 5). Orher Doppler 
variables such as pak early filling velocity, peak early to 
peak alrial filling velocity ratio, mean deceleration rate of 
early iiiiing. dcccsiewion i;mc and acceicraiiw iims *iii- 
no, useful in predicting the development of doxorubicin- 
induced systolic dysfunc,ion. The groups that did and did 
Figure 6. Linear regression anatyalr of percent change in ejection 
fraction WI versus percent change in isovolumetrx retaxrition lime 
~IVRTI 3 weeks after the peak dowrubicin dose in the entire study 
group In = 26). The correlation modeelly improved when the one 
Figure 4. Individual changca in ejection tracl:on from tb.’ control 
study ,C) to ihe c”m”la,we doxorubicin doses I” the nine Qaue”,s 
shown in Figure 3. Abbreviations and convemions as in Figure 3 0.05) to be the only predictor of percent change in ejection 
Note the break m the graph below the ejection fraction of40R. fraction. Other variables such as patient age, peak doxoru- 
bicin dose, presence or absence of hypertension and percent 
not develop systolic dysfunction demonstrated no differ- 
e”cesmage(45 t 12”s. 49 + I2 years, p = NSLgender(Sof 
9 vs. 14 of 17 women, p = NS). total cumulative doxorubicin 
dose I273 2 63 vs. 300 2 ti mglm’, p = NS), presence of 
hypertension t: 019 vs. 4 of 17, p = NS) and control values 
for Doppler indexes and ejection iraction (Tables I and 2). 
For the entire group after the peak doxonbicin dose. the 
percent change in isovolumetric relaxation time weakly 
correlated with Ihr percent change in ejection frac~ton (Fig. 
6). Muluple regression analysis demonstrated the percent 
change in isovolumetric relaxation tome (r = -0.44, p < 
change in oiher Doppler indexes did noi predict the ~&cent 
change in ejection iraction. Lastly, the peak doxorubicin 
dose did not correlate with the percent change in isovoh- 
mctrie relaxation time lr = -0.26, p = NS). 
Early and late effects of doxorubicin. In I5 patients (early 
group) selected at random, peak early filling v&city. peak 
early to peak alrial filling velocily r&o and ejection fraction 
increased and isovolumetric relaxation time shortened I h 
after the first dose of doxotubicin (Table 3). These changes 
returned to cvntrol values 3 weeks later. In 22 patients (late 
group) not receiving medisstinal chest irradiation aRer com- 
tdetion of chemotheraov. oeak ea:lv to Desk atrial filline 
&city rat10. mean &&ration rate 0; early filling ad 
Figure 5. Individual percent changes in novolumetric relaxation ejection fraction decreased significantly and isovolumetric 
tm~e IIVRT) from the control study to the cumulative dose munc. 
diately preceding the dose that resuhed a a signnkant decrease I” 
cjectmn Rxlion in the 9 Qztients who uiiimately developed systolic Table 3. Early ERecl of Doxorubicin on Systolic Faction and 
dyafunctmn IABNL EFI and from the control study to the study Diastolic Fillmg in IS Patients 
afier the peak dose m rbe 17 Qarienls who did not develop systolic 
dyrfunction WL EFI. A 3% cbang in isovot~met~ic relaxation 
Firs1 Doxorubuin Dare ___.. 
Table 4. Late ERect oi Doxorubicin on Systolic Funct~an 2nd 
Diastolic Filline ic 22 Patients 
relaxation time increased after the peak doxorublcm dose 
(Table 4). These changes were still evident 3 months after 
the last doxorubicin dose. 
Variability of echocmdiographie measuremenb. A smgle 
study selected al random for each patient (n = 26) was “red 
to determine inlraobserver variability of ejection fraction 
(5 + 3%). end-diastolic volume (7 ? 6%). end-systo!ic 
volume (g + 6%). peak early filling velocity (2 + 3%). peak 
early to peak atrial filling velocity ratio (5 c 4%). mean 
decelemtion rate of early filling (9 z lOWi. isovolumetrx 
relaxation time (6 ? 8%), deceleration ttme (8 + IO’%1 and 
acceleration time (8 2 6%). A single study selected at 
random from I5 patients was used to determine interob- 
sewer variability of ejection fraction (5 ? 4%). end-diastolic 
volume (7 + 5%), end-systolic volume 19 2 7%). peak early 
filling velocity (3 + 3%). peak early to peak atria1 filling 
velocity ratio (7 = 5%). mean deceleration rate of early filling 
(I3 t 12%). isovolumelric relaxation time (8 2 IO%). dxel- 
eration time (I 1 + 12%) and accelemlion lime (I I ? 6%). To 
determine ponihle biologic variation in measured variables. 
IO Patients selected at random were studied before chemo- 
therapy over a 3.week interval. The 3.week biologic van- 
ability was determined for ejection fraction (5 5 4%). 
end-diastolic volume (5 + 4%). end-systolic volume 19 2 
8%). peak early filling velocity (4 2 3%). peak early to peak 
atrial filling velocity r&c (8 f 6%). mean deceleration rate 
ofearly filling (I7 ? 14%). isovolumelric relaxation time (9 f 
12%), deceleration time (I3 f 13%) and acceleration time 
(12 + 7%). The absolute intraobserver. interobserver and 
3.week biologic differences in ejection fraction were. respsc- 
lively. 3 * 2 ejection fraction uni:s (range II to 5). 3 * 2 
ejection fraction units (range 0 lo RI and 3 * 3 ejection 
fraction units (range 0 to 6). 
make\ I,\ u,c probl :mat,c (4-71. At present. noniwa.we 
te\tmg i\ commonly wed to guide dororubwn chemot?er- 
spy. alihouph cndomyocard;a~biopny delineatea actual myo- 
cadlal damage. it IS invaswe and not routin+ uzsd. Most 
noninvawe te?n have meacured mdexec of syctolic function 
a a man\ ui detecting doxorubicin cardiotoxicity. Srud~es 
uxing cyrlobc time iillerval~ havs shown vanable results (8). 
M-mode echocardiography has not contributed pYdiy toghe 
mon!tortng of cardtac funclion in thts wting. The fractional 
shortemng of the minor diameter of the left ventricle and 
wlocity of c;rcumfcrmtial tiber shortening have been used, 
but are cnt~nlly dependent on synchronous ventricula: \vall 
mxion and lo&g condition;. It is unknown whether 
? :-mode echocardiographrcally dewed indexes of diwotic 
filling are useful predictors of doxombicin cardiotoxicity 
!34). Ewtmn traction has been found useful in the delemti- 
nation of dowrubicin cwdioloxtcily 113). Hoeever. tt IS not 
an Ideal Index and repotis (35) have shown that it correlates 
poorly wlh myocardiat biopsy grades of doxombxin car- 
diotourQ and momc investigators (13-W have questioned 
the semitivity of the rest ejection fraction. The need for a 
sen~+we and specific nomnvasive test of doxorubicin car- 
dioloxlcity prompted the present study. 
Doxorubicin cardiotoxicity. In our study, doxorubicin ad- 
mimstrat:on was found to prolong isovolumetrtc relaxation 
time and decclentiun ttme and to decrease peak early to 
atnal tillmg velocity ratio and decclcration rate of early 
filling. A 37% prolongation of the isovolumetric relaxation 
time was 7RR sensitive and 88% specific in detecting doxo- 
rubicin-induced systolic dysfunction. Other Doppler indexes 
and clinical variables were not predictive of doxorubicin- 
induced change in ejection fraction. Doxorubicin enhances 
diastolic filling and ejection fraction by I h of administration. 
The impairment in diastolic F.lling and systolic function 
induced by doxorubicin Pc~s~sts z3 months after treatment. 
E&et an diastolic function. In a retrospective study. Lee 
et al. (17) showed alterations in left ventricular diastolic 
filling with radionuclide techniques after the completion of 
doxorubicin treament in I2 patients with a left ventricular 
eJection fractton X5%. This study suggested that iilling 
indexes of diastolic function may be more sensitive than 
variables of systolic function. More recently. Marchandise 
et al. (18) showed a significant prolongation in pulsed Oop- 
pier-deriwd isovolumelric relaxation lime and lime to peak 
filling and a decrease in peak early filling velocity, peak early 
to atrml filhng velocity ratio and deceleration rate in I9 
patients receiving a mean cumulittive doxorubicia dose of 
240 f I35 mgim’. In the present study, Cnilar alterations of 
diastolic filling and isovatumewic rrlaation lime were dem- 
onstrared in patients who ultimate!y developed doxorubicin- 
induced systohc dysiunction. Although most of the Doppler 
indexes wore altered by doxoruhicin therapy. the isovolu- 
metric relaxation time was the only Doppler index that was 
significantly prolonged before ejection fraction decreased 
significantly and that predicted doxorubicin-induced systolic 
dysfuncoon. 
The mechanism that accounts for the alteration in isowl- 
umetric relaxation time and tilling is unknown. Although. 
Doppler-derived indexer we not precise measures of intrin- 
sic diastolic function, it ii likely that impairment in left 
ventricular relaxation accounts for the prolonged isovolu- 
metric relaxation time and impaired filling seen with doxo- 
rubicm administration (26.27). No obvious changes in pre- 
load and afterload were evident as assessed by end-diastolic 
volume and systohc blood pressure, respectively. Damage to 
myocardlal membranous structures and mirocbondria have 
been demonstrated aher usual clinical doses of doxorubicin 
and could account for long-term changes in left ventricular 
relaxation and filling (36). 
Early and late-term oiiecta ofdoxorubicin. The early and 
late effects of doxorubicin on isovolumetric relaxation time, 
diastolic filling and ejection fraction smikingly differed. As in 
the study of Brown et al. (191, doxorubicin enhanced left 
veotricula, systolic function, diastolic filling and isovolumet- 
ric relaxation time by I h after administration. The mecha- 
ioism accounting for such changes may ,elate to a positive 
inotropic and lusitropic effect of doxorubicin. Doxorubicin 
may act to increase intracellular calcium concentration by 
inhibiting adenosine triphosphate-dependent sodium- 
potassium channels or enhancing the release of catechol- 
amines (37-39). The late 13 nonths) depression in systolic 
function, diastolic filling and isovolumetric relaxation is 
more likely due to myocardial injury (8.10-12). The degree 
of systolic and diastolic dysfunction did not correlate with 
the cumulative doxorubicin dose. This finding is consistent 
with data from prior studies (5) demoosirating that myocar- 
dial dysfunction due to cellular injury from doxorubicin is 
complex and ooolmcar. 
Limitations of study. Measures of left vemricular ejection 
fraction and volumes are usually deemed most reliable when 
derived from contrast o, radionuclide ventriculography. 
However, the reliable calculation of left venlricular ejection 
fraction and volumes by two-dimensional echocardiography 
using methods identical to those in the present study has 
been demonstrated (28-33). In addition, the accuracy of 
ejection fraction derived by echocardiography is enhanced in 
subjects lacking segmental wall motion abnormalities, as 
was the case in the present study. Patients served as their 
own control and serial changes in ejection fraction should 
reflect woe alwrat~ons of systolic funaion. The relatively 
small interobserver, intraobserveraod biologic variability of 
the two-dimensional echocardiographic measu,ements ap- 
poris this view. Although the rrsuhs of the present study are 
probably applicable to pno, studies utilizing radionuclide- 
derived ejection fraction, this has yet to be shown. In the 
absence of the development of congestive heari fadure, no 
standard definition of doxorubicin cardiotoxicity exists. 
However, the definition used in the present study was 
prorpective. reasonably strict and in parallel with clinical 
guidelines in the use of doxorubicin. 
Conclusions. Prolonged isovolumetric relaxation time 
and impaired diastolic filling were demonstrated with Dop- 
pier echocardiography in patients who ultimately developed 
doxoruhicin-induced systolic dysfunction. Prolnngalion of 
the isovolumetric relaxation time was found to be a useful 
predictor of the development of reduced ejection fraction 
due to doxorubicin. The isovolumetric relaxation time may 
help guide the need for endomyocardial biopsy in patients 
who require higher doses of doxorubicin hut experience no 
depression in ejection fraction. Doxorubicin enhances iso- 
volumetric relaxation, diastolic filling and ejection fraction 
by I h after administration. Abnormalities in isovo~umetric 
relaxation and diastolic filling persist 23 months after dox- 
orubicin administration. 

